Hikma Pharmaceuticals PLC
2023 Annual Report and Accounts and Notice of 2024 Annual General Meeting
LONDON, 22 March 2024: Hikma Pharmaceuticals PLC (the "Company") announces that, the Annual Report and Accounts for the year ended 31 December 2023 (the "Annual Report") and the Notice of the 2024 Annual General Meeting (the "Notice of AGM") are today being made available to shareholders.
The Annual Report and Notice of AGM can be viewed or downloaded from the Company's website at www.hikma.com/investors/2023-annual-report/.
In accordance with Listing Rule 9.6.1 copies of the Annual Report and Notice of AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Helen Middlemist +44 20 7399 2760
Group Company Secretary
22 March 2024
About Hikma
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/positive Fitch)
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.